Skip to main content

Peer Review reports

From: A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer

Original Submission
15 Aug 2023 Submitted Original manuscript
9 Oct 2023 Reviewed Reviewer Report
8 Nov 2023 Reviewed Reviewer Report
24 Nov 2023 Author responded Author comments - Xiaoyan Lin
Resubmission - Version 2
24 Nov 2023 Submitted Manuscript version 2
29 Nov 2023 Author responded Author comments - Xiaoyan Lin
Resubmission - Version 3
29 Nov 2023 Submitted Manuscript version 3
29 Nov 2023 Author responded Author comments - Xiaoyan Lin
Resubmission - Version 4
29 Nov 2023 Submitted Manuscript version 4
4 Dec 2023 Reviewed Reviewer Report
19 Dec 2023 Reviewed Reviewer Report
21 Dec 2023 Author responded Author comments - Xiaoyan Lin
Resubmission - Version 5
21 Dec 2023 Submitted Manuscript version 5
Publishing
22 Dec 2023 Editorially accepted
5 Jan 2024 Article published 10.1186/s12885-023-11790-6

You can find further information about peer review here.

Back to article page